2007
DOI: 10.1016/j.virol.2007.01.038
|View full text |Cite
|
Sign up to set email alerts
|

A site on the influenza A virus NS1 protein mediates both inhibition of PKR activation and temporal regulation of viral RNA synthesis

Abstract: It is not known how influenza A viruses, important human pathogens, counter PKR activation, a crucial host antiviral response. Here we elucidate this mechanism. We show that the direct binding of PKR to the NS1 protein in vitro that results in inhibition of PKR activation requires the NS1 123-127 amino acid sequence. To establish whether such direct binding of PKR to the NS1 protein is responsible for inhibiting PKR activation in infected cells, we generated recombinant influenza A/Udorn/72 viruses expressing … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

8
208
1
1

Year Published

2009
2009
2017
2017

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 248 publications
(223 citation statements)
references
References 44 publications
8
208
1
1
Order By: Relevance
“…Some of the residues reported to interact with the CPSF30 subunit of the polyadenylation complex are highly conserved, namely Leu144, Gly184, Glu186, Asn188 and the highly surface-exposed Trp187. Residues 123-127 have been shown to interact with a dsRNA-dependent serine/ threonine protein kinase R (PKR) (Min et al, 2007). These residues are surface-exposed and Lys126 is conserved (grade 8), while the other residues are variable.…”
Section: Drug Target Sites Of Influenza Ns Proteinsmentioning
confidence: 99%
“…Some of the residues reported to interact with the CPSF30 subunit of the polyadenylation complex are highly conserved, namely Leu144, Gly184, Glu186, Asn188 and the highly surface-exposed Trp187. Residues 123-127 have been shown to interact with a dsRNA-dependent serine/ threonine protein kinase R (PKR) (Min et al, 2007). These residues are surface-exposed and Lys126 is conserved (grade 8), while the other residues are variable.…”
Section: Drug Target Sites Of Influenza Ns Proteinsmentioning
confidence: 99%
“…For this, we picked H17N10 NS1, which shares an average of 45 % identity with NS1 molecules of other virus subtypes (Tong et al, 2012). The non-structural protein NS1 acts at multiple levels to inhibit type I IFN synthesis by direct interaction with host factors or through binding to dsRNA (Chen et al, 1999;Donelan et al, 2003;Gack et al, 2009;Li et al, 2006;Min et al, 2006Min et al, , 2007Tan & Katze, 1998), which allows the virus to overcome host defences and replicate efficiently (Hale et al, 2008). The anti-host immune responses of NS1 are attributed to two functional domains of NS1: one is the N-terminal RNA-binding domain (RBD) (Qian et al, 1995) and the other is the C-terminal effector domain (ED) (Li et al, 1998).…”
Section: Introductionmentioning
confidence: 99%
“…For example, NS1 blocks 29-59-oligoadenylate synthetase-mediated activation of RNase L (Min & Krug, 2006) and limits the induction of IFN-b (Wang et al, 2000;Ludwig et al, 2002). Furthermore, NS1 binds to and inhibits the cytoplasmic dsRNA sensor retinoic acidinducible gene product I (Guo et al, 2007;Mibayashi et al, 2007) and blocks protein kinase R-mediated inhibition of protein synthesis (Bergmann et al, 2000;Min et al, 2007). In addition to its IFN antagonistic activities, NS1 has recently been shown to actively suppress RNA silencing in plant, insect and mammalian cells (Bucher et al, 2004;Delgadillo et al, 2004;Li et al, 2004;Haasnoot et al, 2007).…”
Section: Introductionmentioning
confidence: 99%